home > ict > winter 2021 > pharmacovigilance in the post-covid-19 world


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Cytosurge’s FluidFM Technology Facilitates Multiplex CRISPR Editing and Monoclonal Cell Line Development in less than Three Weeks

Zurich | March 24, 2021 - Cytosurge, a leading global provider for precision single cell manipulation, announced today that its pioneering, patented FluidFM nano-probe enabled CRISPR multiplexing to generate monoclonal multiple Knock-Out cell lines in less than three weeks starting from the day of transfection until the clones have been characterized.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement